Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

When breast cancer recurs or is diagnosed at an advanced stage, treatment is complicated by the diverse nature of the disease, with several molecular subgroups with distinct tumor biology responding differently to different therapies.

A Pharmacist’s Perspective on CDK4/6 Inhibitors

For patients with advanced breast cancer, prognosis remains especially suboptimal, primarily because of acquired pharmacologic resistance. Fortunately, several new drugs and drug combinations have recently become available.

A Payer’s Perspective on CDK4/6 Inhibitors

Breast cancer is not simply one disease, and the use of more effective therapies that target different tumor markers, such as the cyclin-dependent kinase (CDK)4/6 pathway in estrogen receptor–positive breast cancer, may actually reduce the total cost of care for patients/members and payers.

A Nurse Navigator’s Perspective on CDK4/6 Inhibitors

An open conversation with a patient at this transition point of an MBC diagnosis should stress that, although the disease may be incurable, care can focus on control and hope as long as possible, with a balance for quality of life.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: